Financial Data and Key Metrics Changes - In Q4 2024, YUPELRI net sales increased by 10% year-over-year, reaching $66.7 million, marking an all-time high [4] - Full year YUPELRI sales totaled $239 million, with an 8% increase in net sales for 2024 and an 11% growth in demand [11][14] - Collaboration revenue grew by 8% to approximately $19 million in Q4 [32] - Operating expenses, excluding share-based compensation, increased to $22 million due to commercial and medical affairs spending [32] Business Line Data and Key Metrics Changes - YUPELRI's hospital performance saw doses increase by 49% year-over-year, with 285,000 redoses pulled through to hospital customers [12][13] - The hospital business accounts for roughly 10% of total YUPELRI volume, with the remaining 90% coming from community settings [77] - Ampreloxetine is on track for expedited NDA filing, with solid enrollment in the CYPRESS study and positive FDA interactions [5][23] Market Data and Key Metrics Changes - GSK reported full year TRELEGY sales of $3.5 billion, up 26% year-over-year, triggering a $50 million milestone payment to Theravance [15] - The company expects to receive several hundred million in cumulative royalties starting in 2029 based on projected sales [17] Company Strategy and Development Direction - The company aims to grow YUPELRI revenue while increasing brand profitability, with potential near-term milestones in the U.S. and royalties from China [7][14] - There is a focus on completing enrollment in the CYPRESS study and preparing for an expedited NDA filing for ampreloxetine [8][23] - The company is committed to maximizing the value of TRELEGY and returning excess capital to shareholders [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong financial position entering 2025, with $88 million in cash and no debt [39] - The company is focused on driving YUPELRI growth through strong demand generation and a patient-centered strategy [40] - Management highlighted the potential impact of ampreloxetine on patients with MSA suffering from nOH symptoms [41] Other Important Information - The company plans to request priority review for ampreloxetine at the time of NDA filing [23] - The accounting treatment for TRELEGY milestones has been updated, affecting the recognition of other income [37] Q&A Session Summary Question: What drove the success on the hospital channel this quarter? - Management attributed the success to effective execution of strategy and wins in larger systems, leading to increased volume through therapeutic interchange [45][46] Question: What is the trajectory of the hospital performance into 2025? - Management noted that Q1 is typically softer but indicated that the need for YUPELRI is strong due to high hospital census [59][60] Question: What percentage of YUPELRI sales are non-hospital sales dollars? - Management clarified that the hospital business accounts for roughly 10% of total YUPELRI volume, with 90% from community settings [77] Question: What is the bar for success for the CYPRESS readout? - A one-point change in the OHSA composite score is considered clinically meaningful for success [88] Question: Will there be an increase in the commercial organization ahead of the data? - Management stated that no incremental FTEs are planned until after the CYPRESS data readout [93]

Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call February 27, 2025 08:39 AM ET Company Participants Mary Jenkins - Senior Manager of Investor RelationsDouglas Ingram - President & CEODallan Murray - EVP & Chief Customer OfficerLouise Rodino-Klapac - EVP, Chief Scientific Officer & Head Of R&DIan Estepan - EVP & CFOTazeen Ahmad - MD - US Equity ResearchGena Wang - MD - Biotech Equity ResearchKevin Meli - Equity Research AssociateAndrew Tsai - SVPKostas Biliouris - Director - Equity ResearchJoseph Schwartz - ...

Alphatec Holdings, Inc. (NASDAQ:ATEC) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Pat Miles - Chairman and CEO Todd Koning - CFO Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Vik Chopra - Wells Fargo Eric Anderson - TD Cowen Phillip Dantoin - Piper Sandler Matt Miksic - Barclays Caitlin Cronin - Canaccord Genuity Jason Wittes - ROTH David Saxon - Needham Kallum Titchmarsh - Morgan Stanley Operator Good afternoon, everyone, and welcome to the ...

Financial Data and Key Metrics Changes - Total revenue in Q4 was $37.4 million, with core revenue of $36.5 million, reflecting a 10% year-over-year increase [28][29] - GAAP gross margin for Q4 was 36.2%, while non-GAAP gross margin was 40.1%, slightly below expectations due to lower margins in the risk assessment business and higher scrap expenses [31][32] - The company ended Q4 with zero debt and total cash and cash equivalents of $268 million [33] Business Line Data and Key Metrics Changes - Diagnostics revenue grew 9% year-over-year, generating $18.8 million in Q4, driven by strong order trends in the international HIV business [29][13] - Sample management solutions revenue increased 14% year-over-year, totaling $14.8 million in Q4 [29][13] - COVID-19 products contributed $1 million in revenue, consistent with expectations, while the risk assessment testing business generated $2.1 million in Q4 [30] Market Data and Key Metrics Changes - The international diagnostics business generated $41 million in revenue for 2024, with approximately 80% associated with donor-funded programs [15][16] - The company noted elevated uncertainty in the market environment due to freezes on US funding for foreign aid, impacting HIV testing programs in developing countries [15][19] Company Strategy and Development Direction - The company is focused on three strategic pillars: strengthening the foundation, elevating core growth, and accelerating profitable growth [7] - The acquisition of Sherlock Biosciences aims to expand the innovation pipeline with a molecular diagnostic platform [8][24] - The company plans to invest in innovation and expand its product portfolio, particularly in rapid diagnostics and sample management solutions [23][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong positioning despite near-term uncertainties, emphasizing the importance of investments in science and innovation [21][41] - The company is closely monitoring the impact of external factors, including changes in funding for HIV testing programs and NIH research funding [15][19] - Management anticipates that the combination of operational efficiencies and increased volumes will drive gross margin improvements towards the target of 50% [36] Other Important Information - The company generated positive cash flow from operations for the core business in Q4, indicating progress in operating efficiency and cost-saving initiatives [11][12] - The company expects to spend between $20 million and $25 million on the Sherlock acquisition, primarily for clinical trial development [95] Q&A Session Summary Question: What are the key uncertainties in the global market? - Management identified PEPFAR and academic funding as the primary areas of uncertainty, with PEPFAR being closely monitored [44][46] Question: Any updates on the Safarose blood collection device? - The device is still in the regulatory process, with expectations for approval in 2025 [50][51] Question: Can you elaborate on the BARDA contract and its funding? - The $7.5 million from BARDA is expected to be back-end loaded, with potential access to an additional $11 million based on milestones [55][56] Question: What is the outlook for gross margins and scrap expenses? - Scrap expenses were attributed to expired materials and are considered a one-time issue, with expectations for gross margins to improve through operational efficiencies [59][60] Question: How does the company view the potential downside from international government-funded markets? - Management emphasized bipartisan support for life-saving programs and the importance of public health, framing the international business as primarily donor-funded [102][106]

Health Catalyst (HCAT) Q4 2024 Earnings Call February 27, 2025 06:40 AM ET Company Participants Jack Knight - VP - Investor RelationsDan Burton - CEODan Lesueur - COOJason Alger - Chief Financial OfficerJared Haase - Equity Research AssociateAnne Samuel - Executive DirectorSameer Patel - VP - Equity ResearchScott Schoenhaus - Managing DirectorGabrielle Ingoglia - Equity Research Associate Conference Call Participants Jessica Tassan - Senior Equity Research AnalystJohn Pinney - AnalystDaniel Grosslight - Sen ...

Financial Data and Key Metrics Changes - For Q4 2024, gross billings increased by 10% to $2.25 billion compared to $2.05 billion in Q4 2023, while diluted earnings per share rose by 17% to $0.63 from $0.54 in the prior year quarter [30] - For the full year 2024, gross billings grew by 7.9% to $8.3 billion from $7.7 billion in the previous year, and diluted earnings per share increased by 7% to $1.98 from $1.85 [30] - Average billing per worksite employee (WSE) increased by 3.3% in Q4 [32] Business Line Data and Key Metrics Changes - PEO growth billings increased by 10% in Q4, while staffing revenues declined by 9% to $20 million [31] - PEO worksite employees grew by 5.2% in Q4, driven by a record number of WSEs added from new clients [31] - Staffing business declined by 9% year-over-year, but the rate of decline has slowed significantly compared to the previous year [15] Market Data and Key Metrics Changes - Year-over-year PEO gross billings growth by region for Q4: East Coast grew by 21%, Southern California by 11%, Mountain by 10%, Northern California by 5%, and Pacific Northwest declined by 4% [33] - The East Coast region has achieved 15 consecutive quarters of double-digit growth, while the Pacific Northwest is expected to return to growth in 2025 [34] Company Strategy and Development Direction - The company is focusing on expanding its asset-light model and has successfully entered new markets, with 21 new market development managers added [16] - Continued investment in technology and product development is a priority, with multiple product releases planned for 2025 [9][21] - The company aims to enhance its employee life cycle experience through new product launches and technology investments [22][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2025, anticipating gross billings to increase between 7% and 9% and average WSEs to rise between 4% and 6% [43] - The company expects continued growth in net client adds and modest improvements in client hiring [44] - Management noted that wage inflation remains stable and is a baseline driver of growth [49] Other Important Information - The company achieved a Net Promoter Score increase of 5 points to 69, indicating strong client satisfaction [10] - The balance sheet remains strong with $122 million in unrestricted cash investments and no debt [40] - The company repurchased over 3% of its outstanding shares in 2024, totaling more than $29 million [42] Q&A Session Summary Question: Insights on client hiring and wage inflation - Management noted stability and recovery in hiring metrics, with consistent wage inflation being a driver of growth [49] Question: Average WSE growth and client contributions - The majority of WSE growth is expected to come from new clients and client retention [52] Question: Healthcare revenue mechanics - The company earns through reseller fees and administrative fees, with plans to disclose more detailed metrics in the future [60] Question: Technology investments and client attraction - Technology initiatives have been enhanced to support non-traditional clients and larger clients, with a focus on software to support business operations [67] Question: Workers' compensation pricing trends - Management indicated a deceleration in rate decreases for workers' compensation, with hopes for a market turnaround soon [80] Question: Impact of California wildfires - Minimal impact on employees and clients was reported, with potential future business opportunities arising from rebuilding efforts [84][87] Question: Competitive positioning in benefits - The company emphasizes its strong local teams and expanding product offerings as key differentiators in the market [96]

Kura Oncology, Inc. (NASDAQ:KURA) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Patti Bank - IR Troy Wilson - President and CEO Mollie Leoni - CMO Tom Doyle - SVP of Finance and Accounting Brian Powl - CCO Conference Call Participants Li Watsek - Cantor Fitzgerald Yen-Der Li - Leerink Partners Jason Zemansky - Bank of America Peter Lawson - Barclays Dara Azar - Stifel Charles Zhu - LifeSci Capital David Dai - UBS Justin Zelin - BTIG George Farmer - Scotiabank Operator Go ...

Encore Capital Group (ECPG) Q4 2024 Earnings Call February 27, 2025 05:32 AM ET Company Participants Bruce Thomas - VP, Global Investor RelationsAshish Masih - President & Chief Executive OfficerJonathan Clark - EVP, CFO & TreasurerDavid Scharf - Managing DirectorMike Grondahl - Head of Equities & Director of ResearchJohn Rowan - Managing DirectorRobert Dodd - Director - Finance Conference Call Participants Mark Hughes - Analyst Operator Good day, everyone, and thank you for standing by. Welcome to the Enco ...

Perfect Corp (PERF) Q4 2024 Earnings Call February 27, 2025 05:29 AM ET Company Participants ​Jamie Shah - Director - Investor RelationsAlice H. Chang - Founder, Chairwoman of the Board & CEOPin-Jen Chen - Executive VP & Chief Strategy Officer Conference Call Participants Patrick McCann - Equity Research AnalystLisa Thompson - Senior AnalystAashi Shah - Equity Research Analyst Operator We will be hosting a question and answer session after the management's prepared remarks. Please note that today's event is ...

Joby Aviation (JOBY) Q4 2024 Earnings Call February 27, 2025 05:24 AM ET Company Participants Teresa Thuruthiyil - Head of Investor RealtionsJoeBen Bevirt - Founder and Chief Executive OfficerPaul Sciarra - Executive ChairmanSavanthi Syth - MD - Airlines & Advance Air MobilityDidier Papadopoulos - President of Aircraft OEMBill Peterson - Equity ResearchAustin Moeller - Director - Equity Research Conference Call Participants Andres Sheppard - AnalystChris Pierce - Senior AnalystDavid Zazula - AnalystEdison Y ...